IDEX Biometrics ASA – EX. SHARE CONSOLIDATION (REVERSE SPLIT) TODAY
Previous ISIN: NO0013107490 New ISIN: NO0013536078
For further information contact:Anders Storbråten, CEO and CFOE-mail: anders@idexbiometrics.com
About this noticeThis notice was published by Erling Svela, Vice president of finance, on 4 July 2025 at 08:00 CET on behalf of IDEX Biometrics ASA. The information shall be disclosed according to Continuing Obligations at Oslo Børs Euronext and is published in accordance with section 5‑12 of the Norwegian Securities Trading Act.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 hours ago
- Yahoo
Wealthy Europeans Moving to Tax Havens Are Getting Hit With Exit Charges From Their Home Countries
Wealthy Europeans looking to depart from their high-tax countries are facing some rather high-priced headwinds. Affluent residents across the continent are now facing exit levies before they make the move to tax havens such as Monaco, Dubai, and Switzerland. This is a result of some nations' efforts to slow down—or even halt—the departure of these ultrahigh-net-worth individuals, Bloomberg reported. More from Robb Report This New 100-Foot Superyacht Is a Hard-Top Convertible for the Seas One of Texas's Best Distilleries Just Released Its Oldest Bottled in Bond Bourbon Yet The Next James Bond Film Will Be Directed by Denis Villeneuve of 'Dune' With the exit tax, countries are aiming to collect a portion of the profits that a person has generated while using that nation's infrastructure to build their assets. The implementation has faced criticism, since individuals are required to pay levies on unsold assets. Even so, exit taxes have become more prevalent in the past year: Recovery from the Covid-19 pandemic, among other expenses for the public, and slower growth overall has left European governments searching for ways to increase funds, according to Bloomberg. 'A lot of countries are bringing in exit taxes,' David Lesperance, founder of wealth management company Lesperance & Associates, told Bloomberg. 'Clients who have illiquid assets and mortgages are then hesitant to trigger [them] because they just don't have the money to pay the bill.' In particular, Germany, Norway, and Belgium have either increased their exit levies as of late or have considered doing so. The Scandinavian country can hit well-off residents with a tax of up to 38 percent on their unrealized capital gains. As for Germany, where the exit-tax system rose back in the 1960s, it hovers around 27 percent with its levies. It can affect those leaving the country who own 1 percent or more, of a company's shares—or if they lay claim to around $581,000 (€500,000) of a brand's equity. The exit taxes have certainly had an impact—in one instance, the owner of a German IT company kept his daughter out of his succession plans to avoid paying a high levy on the transferred assets, Bloomberg reported. These aren't the only countries where the UHNW are on the move, either. Last April, the U.K.'s removal of its over 200-year-old tax-break system for 'non doms,' a nickname for the nation's foreign residents, caused an exodus of ultra-wealthy individuals to leave the nation. Many of those folks have decided to settle down in Italy—specifically, in the financial hub of Milan—where they can pay a flat levy of $223,000 to avoid Italian taxes on earnings overseas, mirroring what was previously done in the United Kingdom. As a result of the U.K. tax upheaval and the UHNW migration, some have called for the government to create an exit tax on the country's well-to-do residents before they take flight. For now, though, the nation had made no moves to do so, Bloomberg reported. Click here to read the full article. Sign in to access your portfolio
Yahoo
11 hours ago
- Yahoo
Schlumberger JV OneSubsea Secures Contract for Northern Lights CCS Project Expansion in Norway
Schlumberger Limited (NYSE:SLB) is one of the best NYSE stocks to buy for long-term investment. On June 25, OneSubsea, which is a joint venture of global technology company SLB, announced that it had secured an Engineering, Procurement, and Construction/EPC contract from Equinor for Phase 2 of the Northern Lights carbon capture and storage/CCS project offshore Norway. This contract marks a significant progression for the project, following the final investment decision/FID made by Northern Lights' owners (TotalEnergies, Shell, and Equinor) and a commercial agreement with an end-use customer. With the completion of Phase 2, the project's capacity is set to expand significantly, from its initial 1.5 million tonnes/mt of CO₂ per year to a minimum of 5 mt per year. An aerial view of a well site, depicting the scale of oil and gas operations. The scope of the contract awarded to SLB OneSubsea includes the engineering and construction of two new satellite subsea CO₂ injection systems along with their associated tie-in equipment. Project work has already commenced, with initial deliveries anticipated in 2026. Schlumberger Limited (NYSE:SLB) provides technology for the energy industry worldwide. While we acknowledge the potential of SLB as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
11 hours ago
- Yahoo
Jazz Pharmaceuticals' Ziihera Receives Conditional European Approval for Advanced Biliary Tract Cancer
Jazz Pharmaceuticals (NASDAQ:JAZZ) is one of the best high short interest stocks with huge upside potential. On July 2, Jazz Pharmaceuticals announced that the European Commission/EC had granted conditional marketing authorization for its new bispecific antibody, called Ziihera (zanidatamab), for the treatment of biliary tract cancer/BTC. The approval extends to all European Union member states, as well as Norway, Iceland, and Liechtenstein. Ziihera is authorized as a single agent for adults with unresectable locally advanced or metastatic HER2-positive (IHC 3+) BTC who have previously received at least one line of systemic therapy. The recommended dose for zanidatamab is 20mg/kg, administered intravenously every two weeks, until disease progression or unacceptable toxicity. A biopharmaceutical scientist in their lab, studying a newly-diagnosed therapy-related acute myeloid leukemia. . The EC's decision was supported by data from the Phase IIb HERIZON-BTC-01 trial, which included 87 participants with previously treated, locally advanced or metastatic HER2-positive BTC. The continuation of this conditional approval depends on further clinical benefits being demonstrated in the ongoing Phase III HERIZON-BTC-302 trial. Jazz Pharmaceuticals (NASDAQ:JAZZ) identifies, develops, and commercializes pharmaceutical products in the US, Europe, and internationally. While we acknowledge the potential of JAZZ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey.
